Can-Fite BioPharma
  • ABOUT
    • Overview
    • Management
    • Drug Development Team
    • Board of Directors
    • Corporate Partnerships
  • SCIENCE
    • Technology Platform
    • Scientific Publications
  • PIPELINE
    • Overview
    • Piclidenoson (CF101)
    • Namodenoson (CF102)
    • CF602
    • Cannabinoids
  • INVESTORS
    • Overview
    • News & Events
    • Company Information
    • Financial Information
    • Stock Information
    • SEC Fillings
    • Corporate Governance
    • Shareholders Meetings
  • CONTACT

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • In The News
    • Research
    • Events Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Video
    • Management
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Governance Documents
  • Shareholders Meetings
  • News & Events

  • Overview
  • Press Releases
  • In The News
  • Research
  • Events Calendar
  • Presentations
  • Email Alerts
Jan 09, 2020 9:10am EST

Can-Fite Announces Exercise of Warrants for Cash Proceeds of $2.4 Million

Jan 07, 2020 8:20am EST

Data from the Phase II Liver Cancer Study with Namodenoson will be presented at the ISCORT Conference by Dr. Stemmer

Jan 06, 2020 7:00am EST

Can-Fite CEO Issues Letter to Shareholders

Jan 03, 2020 7:00am EST

New Data From Hadassah Medical Center Lab Show Can-Fite’s Namodenoson Induces Weight Loss

Dec 26, 2019 7:00am EST

Golan Bitton Univo Pharmaceutical CEO Elected to the Can-Fite Board: A Strategic Partnership with Univo to Develop Cannabinoid-Based Products is Ongoing

Dec 09, 2019 8:15am EST

Can-Fite Completes 50% Patient Enrollment in its Phase III Psoriasis Trial

Dec 05, 2019 7:00am EST

Can-Fite to Attend BioFIT 2019 Conference in Europe with Focus on Partnering Meetings for Namodenoson in NASH

Nov 29, 2019 7:00am EST

Can-Fite Reports Third Quarter 2019 Financial Results & Provides Clinical Update

Nov 21, 2019 7:00am EST

Can-Fite BioPharma to Hold Investor Webinar and Q&A Session with CEO on November 25, 2019

Nov 19, 2019 7:00am EST

Can-Fite Granted Patents for its Sexual Dysfunction Drug

  • arrow_back
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 38
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • HOME
  • CONTACT

© 2023 Can-Fite All Rights Reserved

BrandWiz - Branding